FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza™) for injectable suspension

Oncologist

Volumn 10, Issue 3, 2005, Pages 176-182

  Kaminskas, Edvardas ^a   Farrell, Ann T ^a   Wang, Yong Cheng ^a   Sridhara, Rajeshwari ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Azacitidine; Leukemia; Myelodysplastic syndromes; Refractory Anemia; Vidaza

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTHRALGIA; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; ECCHYMOSIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPOTENSION; INJECTION SITE REACTION; INSOMNIA; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; RIGOR; SEPSIS; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOOD TRANSFUSION; DRUG APPROVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 16244400457     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-3-176     Document Type: Review

References (18)

1. Jones PA, Taylor SM, Wilson VL. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 1983;84:202-211.
2. Glover AB, Leyland-Jones B. Biochemistry of azacitidine: a review. Cancer Treat Rep 1987;71:959-964.
3. Li LH, Olin EJ, Fraser TJ et al. Phase specificity of 5-azacytidine against mammalian cells in tissue culture. Cancer Res 1970;30:2770-2775.
4. Vesely J. Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells. Pharmacol Ther 1985;28:227-235.
5. Friedman S. The inhibition of DNA(cytosine-5)methylases by 5-azacytidine. The effect of azacytosine-containing DNA. Mol Pharmacol 1981;19:314-320.
6. INK4B gene in myelodysplastic syndromes. Blood 1997;90:1403-1409.
7. INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17:1813-1819.
8. Chabner BA, Drake JC, Johns DG. Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochem Pharmacol 1973;22:2763-2765.
9. Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Interm Med 1976;85:237-245.
10. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
11. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429-2440.
12. Silverman LR, Holland JF, Demakos EP et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 1994;68:A12.
13. Silverman LR, Holland JF, Ellison RR. Low dose continuous infusion azacytidine is an effective therapy for patients with myelodysplastic syndromes, a study of Cancer and Leukemia Group B. J Cancer Res Clin Oncol 1990;116 (suppl):816.
14. Chitambar C, Libnoch JA, Matthaeus WG et al. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 1991;37:100-104.
15. Gryn J, Zeigler ZR, Shadduck RK et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res 2002;26:893-897.
16. Jani CR, Pechet L, Ballen KK et al. 5-Azacytidine treatment of patients with myelodysplastic syndrome results in resolution of red cell transfusion dependence for some patients, and for 1 patient with transformed AML (t-AML) elimination of marrow blasts for nearly 2 years. Blood 2001;98:272b.
17. Rugo H, Damon L, Ries C et al. Compassionate use of subcutaneous 5-azacytidine (AzaC) in the treatment of myelodysplastic syndromes (MDS). Leuk Res 1999;23:S72.
18. Rugo H, Damon L, Ries C et al. Treatment of myelodysplastic syndromes (MDS) with SC 5-azacytidine (AzaC). Blood 1994:317a.